Compare ALVO & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALVO | EOS |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Luxembourg | United States |
| Employees | 1460 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2004 |
| Metric | ALVO | EOS |
|---|---|---|
| Price | $3.06 | $21.34 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 638.7K | 98.4K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.28 | N/A |
| Revenue Next Year | $18.63 | N/A |
| P/E Ratio | $18.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $19.44 |
| 52 Week High | $9.94 | $24.49 |
| Indicator | ALVO | EOS |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 34.95 |
| Support Level | $2.99 | $21.16 |
| Resistance Level | $3.94 | $22.99 |
| Average True Range (ATR) | 0.17 | 0.26 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 0.98 | 5.09 |
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.